Objectives: The aim of our investigation was to detect mutation or genetic polymorphisms in MGMT gene of esophageal cancer patients from Kashmir Valley (India)
Introduction
Esophageal cancer is one of the most common cancers occurring globally (1) and is a major cause of cancer related deaths in India. The high incidence areas in India includes North-East India (2) and Kashmir valley (3) where environment and dietary habits play an overwhelming role in the development of Esophageal cancer over the genetic factors. These include intake of sun-dried vegetables of Brassica family (Hakh), pickled vegetables (Anchar) and hot salted tea, which contains potentially high content of carcinogenic compounds like nitrosamines. (4) (5) (6) (7) (8) Nitroso compounds are the alkylating agents which induce the formation of O 6 alkylguanine adducts. The ability of these adducts to pair with thymine instead of cytosine during DNA replication and is responsible for the increase in the frequency of transition mutations following exposure to alkylating agents, and determines their mutational spectrum. The toxic and recombinogenic effect of O6-alkylguanine lesions, in particular the methyl version, is determined by the action of the post-replication mismatch repair system on O 6 -methylguanine (O 6 -meG): T mispairs, although the precise mechanisms of these effects remain to be established.
The Methylguanine DNA adducts. These include defence against point mutations, cancer initiation and progression, sister chromatid exchanges, chromosomal aberrations and apoptosis. (9) (10) (11) (12) (13) (14) Genetic analysis of MGMT gene has shown that it is not frequently mutated in human cancers. There has been only two reports describing MGMT mutations and deletions and this was in a substantial proportion of tumours of the oesophagus and colon cancer . (15, 16) Moreover, several studies have reported the existence of five genetic variants of the coding regions of the MGMT gene, four of which lead to alterations in the amino acid sequence of the protein. The currently known variants affecting the primary structure of MGMT are: W65C; L84F; I143V/K178R and G160R. (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) The SNPs leading to the I143V and K178R changes are in almost perfect disequilibrium (19, 20, 26, 28) and it can be assumed that both changes occur in the protein derived from this gene but in some cases only one of the alterations was tested for. There is also a silent mutation with a C to T variation at codon 53 encoding Leu.
The genetic status of MGMT gene has been analysed in various types of cancers and in different populations. In this study, we made an attempt to investigate the molecular status of MGMT gene in esophageal cancer patients from Kashmiri population which is highly exposed to dietary as well as tobacco specific nitrosamines.
Materials and Methods

Study population
A total of 30 surgically resected esophageal tumor tissues and their adjacent normal tissue were used for mutational analysis. To screen the novel polymorphism, identified after mutational analysis, the blood samples of 71 esophageal cancer patients and 60 healthy individuals without overt cancer were recruited in this study. The histological type of the tumors was diagnosed on the basis of resected specimens in the Department of Pathology of the same hospital. The healthy participants, who have no history or diagnosis of cancer or genetic disease, were recruited from individuals who visited the same hospital for physical examination during the same period. The cancer patients and control participants were all of unrelated Kashmiri nationality from Kashmir Valley and its surrounding regions.
All subjects were interviewed using a structured questionnaire to obtain information on patients' age, area of residence, lifetime history of tobacco, occupational history, family history of malignancy, dietary habits etc. The study was approved by the Ethics Committee of Sher-I-Kashmir Institute of Medical Sciences and informed consent was obtained from all recruited participants. DNA extraction DNA was isolated from the peripheral blood or normal and cancerous esophageal tissues of subjects using the phenol/chloroform extraction after proteinase K digestion. (30) PCR amplification and DNA sequencing
The MGMT coding regions (exons 2-5), were amplified by PCR. The primers used for exons 2-4 were designed using primer3software and included splice junctions also. The primer for exon5 has been described as previously. (31) The primer sequences and the size of amplicons are listed in the Table1. Each PCR was performed under standard conditions in a 25 μL reaction mixture containing 100 ng of template DNA, 2.5 μL of 10 × PCR buffer, 1.5 mM MgCl 2 , 1 unit of Taq-DNA polymerase, 200 μM of deoxynucleotide triphosphate (dNTP) and 5 pmol of each primer. Each PCR was performed for 5 min at 95°C followed by 35 cycles at 95°C for 35 s, 54°C (for exon2 and exon 4) or 65°C (for exon3) or 62 °C (for exon5) for 35 s, and 72°C for 1 min (for exons 2, 3 and 4) or 30 s (for exon5), followed by a final extension step at 72°C for 7 min in a Biorad thermal cycler. Nucleotide sequencing of 30 tumor and their adjacent normal tissues was performed in both directions using the Big Dye method and an automatic sequencer ABI 377 (Applied Biosystems). Sequencing primers were the same as those used for PCR. mutations or polymorphisms were detected in exon 2 and 4. Six patients showed L53L and L84F polymorphism in exon3.The two polymorphisms were in linkage disequilibrium. Among the 6 patients, heterozygous variant was found in 4 patients (13.33%) and homozygous variant in 2 patients (6.66%). Moreover, 5 patients showed I143V and L178R polymorphisms in exon 5 which were in linkage disequilibrium. The two polymorphisms in all the 5 patients in exon 5 were heterozygous variants (16.66%).
We also identified two somatic mutations in the intron 4, one in the 5 ' splice donor site c.274 +4G>A. (Fig.1) and another at c.274 + 22G>A. (Fig.2) . Splice site mutation was found in 2 out of 30 cases (6.66%) and c.274 + 22G>A mutation was found in only 1 out of 30 cases(3.33%).
(a) (b) A novel germline variation c.459A>G (p.Gly153Gly) was found in only one case (coded as T2) in exon5 (Fig.3) .This germline variation was screened in 71 esophageal cancer patients and 60 healthy controls by a novel PCR-RFLP approach. RFLP confirmed the presence of this novel variation in the patient T2 (1.4%) (Fig.4) . But none of the 70 patients and 60 healthy controls showed this variation. This inconsistency could be due to the fact that the three studied populations belong to different geographical regions.
In our study, we have found the already well known 2SNPs L53L and L84F in the exon 3 of the MGMT gene. The frequency of these SNPS as mentioned in the results cannot be taken as absolute, because only 30 esophageal cancer tissues were directly sequenced. The frequency of these SNPs is well documented in the literature. (17) (18) (19) (20) (21) (22) However, preliminary observations reveal that the 2SNPs L53L and L84F are in linkage disequilibrium in our study which is in contrast to other studies. Again this could be due to small number of samples involved in our study.
The sequencing analysis of the exon5 of the MGMT gene in our study led to the identification of two well documented SNPs I143V and Ll78R which are in linkage disequilibrium. (19, 20, 26, 28) The association of these two non-synonymous SNPs with the susceptibility of various types of cancers have been studied by various workers.
(17-29) Our preliminary results of these SNPs seem to be no different from others.
To the best of our knowledge, we are for the first time reporting (a) the presence of Splice site mutation in the donor site (b) the germline variation at codon 153 (exon5) of the MGMT gene in esophageal cancer patients from Kashmir Valley-a high Incidence area.
The identification of the somatic splice mutation in the donor site of the MGMT gene in our study is in agreement with the fact that somatic splice-site mutations are known for a number of familial cancer syndromes and the corresponding tumor suppressor genes such as BRCA1, APC, p53, FHIT, and LKB1 and, the prostate cancer susceptibility gene KLF6. (32) (33) (34) (35) (36) Most disease causing single nucleotide substitutions in donor or acceptor splice sites involve the +1/+2 or -1/-2 position, respectively. (37) But in our study the single nucleotide substitution is at +4 position. However, the +4 mutation has been found in a number of genes like BTK, IVD, NF1, SPTB and WT1. In our study we have also identified a splice site mutation at +22 position of intron 4. Mutation at this position is usually rare such as in IDS gene. (38) The functional studies of the splice site mutations at donor or acceptor sites and at the positions which are close or fairly distant from these sites have been carried out by a number of workers. It has been established that mutations in splice sites decrease recognition of the adjacent exon and consequently inhibit splicing of the adjacent intron. (39, 40) Splice site mutations may result in exon skipping, activation of cryptic splice sites, creation of a pseudo-exon within an intron, or intron retention. (41) The functional reason why alterations in positions close to the splice sites may cause aberrant splicing is usually due to the disruption of interactions with U1 snRNP, U6 snRNP, and U2AF 65 or 35 in the splicing process. (42) There is possibility that the splice site mutations found in our study may lead to the formation of splice variants in the MGMT gene. However, effect of these splice mutations on splicing of MGMT gene can be validated by functional studies.
The presence of germline variation c.459A>G (p.Gly153Gly) in only one among the 71 esophageal cancer patients and not in 60 healthy controls, suggests that it could be a rare polymorphism or a germline mutation. It could not be a PCR artefact because it has been confirmed by new PCR based RFLP approach and non-radioactive SSCP (data not shown). The significance of this synonymous germline variation with respect to the etiology of esophageal cancer can be understood on a large case control study. Recently, KimchiSarfaty et al. observed that synonymous single-nucleotide polymorphisms (SNPs) that retain the amino acid sequence can nevertheless result in a protein with an altered structure and function. (43) This finding underscores the fact that synonymous mutations are as important as nonsynonymous.
There are 2835 germline variants of MGMT gene deposited in the human SNP database of NCBI. Besides this, Mihi Yang et al has found an apparent 10 bp-deletion in the intron before exon 5 of the MGMT gene by DNA sequencing. Because this ''deletion'' was observed in all sequenced samples (N = 20), they have suggested that the previously reported human (Caucasian) MGMT gene sequence should be revised to exclude this 10 bp segment. (44) From this, it can be concluded that c.459A>G (p.Gly153Gly) germline variation may be another germline variant of the MGMT gene from Kashmiri populationIndia.
In conclusion, our study has found the new sequence variants of the MGMT gene in esophageal cancer patients from Kashmir valley whose functional significance needs to be validated by other assays. 
